MED22. a subunit of the Mediator complex, plays a critical role in regulating RNA polymerase II (Pol II)-dependent transcription. The Mediator complex acts as a molecular bridge between transcription factors and the basal transcriptional machinery, facilitating the initiation and elongation phases of gene expression. MED22 (also known as MED17 in some contexts) is evolutionarily conserved and contributes to the structural integrity of the Mediator’s middle module, which is essential for stabilizing interactions between Mediator, Pol II, and regulatory proteins. Studies have shown that MED22 is involved in diverse cellular processes, including cell cycle progression, differentiation, and stress responses. Dysregulation of MED22 has been linked to diseases such as cancer, where altered Mediator activity can drive oncogenic transcription programs.
Antibodies targeting MED22 are vital tools for investigating its function and interactions. These antibodies are typically developed using immunogenic peptides or recombinant protein fragments, validated for specificity via techniques like Western blotting, immunofluorescence, or chromatin immunoprecipitation (ChIP). They enable researchers to map MED22’s localization, protein-protein interactions, and its role in gene-specific regulatory mechanisms. Recent applications include studying Mediator complex dynamics in single-cell assays or CRISPR-based screens. However, challenges remain in distinguishing MED22 from homologous subunits or splice variants, emphasizing the need for rigorous validation. Overall, MED22 antibodies are indispensable for unraveling transcriptional regulation and its pathological disruptions.